KD025
KD025 is a selective oral inhibitor of ROCK2, a protein that plays a significant role in immune diseases. It is currently being developed by Kadmon Holdings, a biopharmaceutical company, for the treatment of various autoimmune diseases and fibrosis.
Mechanism of Action[edit | edit source]
KD025 works by selectively inhibiting the activity of ROCK2, a Rho-associated protein kinase. This inhibition leads to a decrease in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines. This shift in cytokine production can help to reduce inflammation and fibrosis in various diseases.
Clinical Trials[edit | edit source]
KD025 has undergone several clinical trials to evaluate its safety and efficacy in treating various conditions. These trials have shown promising results, with KD025 demonstrating significant improvements in patients with chronic graft-versus-host disease (cGVHD), systemic sclerosis, and idiopathic pulmonary fibrosis (IPF).
Chronic Graft-Versus-Host Disease[edit | edit source]
In a Phase 2 clinical trial, KD025 showed significant efficacy in treating patients with cGVHD who had previously failed to respond to standard treatments. The trial found that KD025 was well-tolerated and led to a significant improvement in symptoms.
Systemic Sclerosis[edit | edit source]
A Phase 2 trial of KD025 in patients with systemic sclerosis also showed promising results. The trial found that KD025 led to a significant reduction in skin fibrosis, a common symptom of systemic sclerosis.
Idiopathic Pulmonary Fibrosis[edit | edit source]
KD025 is currently in a Phase 2 trial for the treatment of IPF. Preliminary results have shown that KD025 can significantly reduce lung fibrosis and improve lung function in patients with IPF.
Side Effects[edit | edit source]
The most common side effects of KD025 include nausea, fatigue, and diarrhea. However, these side effects are generally mild and manageable.
Future Developments[edit | edit source]
KD025 is currently undergoing further clinical trials to evaluate its potential in treating other autoimmune diseases and fibrotic conditions. If these trials are successful, KD025 could become a significant new treatment option for patients with these conditions.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
